A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP

Condition:   HIV Infections Interventions:   Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48);   Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48);   Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48);   Drug: Control PrEP:TDF /FTC once daily (weeks 0-26);   Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors:   MRC/UVRI Uganda Research Unit on Aids;   Imperial College London;   University College, London;   International AIDS Vaccine Initiative;   EuroVacc Foundation;   Medical Research Council, South Africa;   National Institute for Medical Research, Tanzania;   Muhimbili University of Health and Allied Sciences;   Instituto Nacional de Saúde, Mozambique;   Ludwig-Maximilians - University of Munich;   King's College London;   Centre Hospitalier Universitaire Vaudois;   Karolinska Institutet;   CONRAD;   Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination. Methods: Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and w...
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Conclusion: Volunteers showed a sustained high commitment. No long-term safety alert was identified during the postvaccine follow-up. Participating in vaccine trials did not increase risky behaviors for HIV infection. Vaccine-induced seropositivity may persist for more than 23 years after receiving rgp160.
Source: AIDS - Category: Infectious Diseases Tags: EPIDEMIOLOGY AND SOCIAL Source Type: research
Vaccine knowledge and anticipated rates of vaccination even lower for pneumococcal disease
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Pediatrics, Pharmacy, Pulmonology, Rheumatology, Institutional, Source Type: news
Conclusion Enthusiasm unabated, however, new tenofovir-sparing antiretroviral regimens are becoming popular and might account for a resurgence of OBI in the HIV setting.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
CONCLUSIONS The qualification and expansion of communication strategies on sexuality in schools is urgent and essential in HIV and AIDS prevention in adolescence, contrary to the current trend of restricting the discussion of these topics in education policies.RESUMO OBJETIVO Analisar a concep ção de jovens soropositivos sobre como prevenir a infecção pelo HIV. MÉTODOS Estudo qualitativo por meio de entrevistas semiestruturadas com jovens soropositivos cujo diagnóstico foi feito na adolescência havia no máximo 5 anos. Seguimos roteiro semiestruturado contendo dados soc...
Source: Revista de Saude Publica - Category: International Medicine & Public Health Source Type: research
In conclusion, he pointed to the “profound” challenges we face, saying: “I am confident that if we continue and strengthen international co-operation and seize the opportunities already available, while creating even more opportunities, we can overcome them – together”.   ‘A political choice’ Universal health coverage means all people regardless of their ability to pay, having access to the health care they need, when and where they need it, without facing financial hardship. Congratulating world leaders, Tedros Adhanom Ghebreyesus, Director-General at the World Health Or...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Development & Aid Global Headlines Health Human Rights Source Type: news
As the AIDS epidemic unfolded, the appearance of opportunistic infections in at-risk persons provided clues to the underlying problem: a dramatic defect in cell-mediated immunity associated with infection and depletion of CD4+ T lymphocytes. Moreover, the emergence of HIV-associated malignancies in these same individuals was a clear indication of the significant role effective cellular immunity plays in combating cancers. As research in the HIV field progressed, advances included the first demonstration of the role of PD-1 in human T cell exhaustion, and the development of gene-modified T cell therapies, including chimeric...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
No abstract available
Source: AIDS - Category: Infectious Diseases Tags: Errata Source Type: research
More News: African Health | AIDS Vaccine | HIV AIDS | Mozambique Health | Research | Study | Tanzania Health | Vaccines